vlog

[Skip to Navigation]
Sign In
Correction
October 16, 2024

Error in Figure

JAMA Dermatol. 2024;160(11):1257. doi:10.1001/jamadermatol.2024.4573

The Original Investigation titled “Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation,”1 published online July 17, 2024, and in the September 2024 print issue, was corrected to fix an error in Figure 1A. The table of numbers at risk was incorrectly labeled in the first column. The labels should have been “Well-controlled disease,” “Adverse effects,” “Ineffectiveness,” and “Total.” The numbers provided in the table were correct. This article was corrected online.

Reference
1.
Soegiharto  R, Alizadeh Aghdam  M, Sørensen  JA,  et al.  Multinational drug survival study of omalizumab in patients with chronic urticaria and potential predictors for discontinuation.   JAMA Dermatol. 2024;160(9):927-935. doi:
×